RESMED INC RMD
Surgical & Medical Instruments & Apparatus ยท NYSE, OTC
์์ต
$4.69B
+10.9% ๋
๋๋
๋
์์์ต
$1.02B
+13.7% ๋
๋๋
๋
์ด ์์ฐ
$8.17B
+18.9% ๋
๋๋
๋
EPS
6.92
+13.6% ๋
๋๋
๋
Advertisement
Income Statement
| ๊ธฐ๊ฐ | 2027 Q1 | 2026 FY | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 FY | 2025 Q3 | 2025 Q2 |
|---|---|---|---|---|---|---|---|---|
| Revenues | $1.34B | $4.69B | $3.80B | $2.51B | $1.22B | $4.22B | $3.46B | $2.27B |
| Cost of Revenue | โ | โ | โ | โ | โ | โ | โ | โ |
| Gross Profit | $817.66M | $2.66B | $2.23B | $1.47B | $717.22M | $2.36B | $1.94B | $1.25B |
| R&D Expense | $89.48M | $307.52M | $244.84M | $160.90M | $79.52M | $287.64M | $226.66M | $149.59M |
| SG&A Expense | $281.65M | $917.14M | $725.89M | $480.59M | $238.98M | $874.00M | $674.95M | $445.03M |
| Operating Income (Loss) | $446.54M | $1.32B | $1.23B | $804.55M | $387.31M | $1.13B | $938.68M | $564.09M |
| Interest Expense | โ | โ | โ | โ | โ | โ | โ | โ |
| Net Income (Loss) | $348.54M | $1.02B | $311.36M | $311.36M | $311.36M | $897.56M | $219.42M | $219.42M |
| EPS (Diluted) | 2.37 | 6.92 | 6.93 | 4.45 | 2.11 | 6.09 | 4.94 | 2.90 |
์ฌ๋ฌดํ
| ๊ธฐ๊ฐ | 2027 Q1 | 2026 FY | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 FY | 2025 Q3 | 2025 Q2 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $8.97B | $8.17B | $8.17B | $8.17B | $8.17B | $6.87B | $6.87B | $6.87B |
| Current Assets | $4.32B | $3.51B | $3.51B | $3.51B | $3.51B | $2.36B | $2.36B | $2.36B |
| Cash & Equivalents | $1.47B | $1.21B | $1.21B | $1.21B | $1.21B | $238.36M | $238.36M | $238.36M |
| Accounts Receivable | $1.04B | $939.49M | $939.49M | $939.49M | $939.49M | $837.27M | $837.27M | $837.27M |
| Inventory | $945.80M | $927.71M | $927.71M | $927.71M | $927.71M | $822.25M | $822.25M | $822.25M |
| PP&E (Net) | $581.83M | $550.79M | $550.79M | $550.79M | $550.79M | $548.02M | $548.02M | $548.02M |
| Goodwill | $2.91B | $3.05B | $3.05B | $3.05B | $3.05B | $2.84B | $2.84B | $2.84B |
| Total Liabilities | $2.38B | $2.21B | $2.21B | $2.21B | $2.21B | $2.01B | $2.01B | $2.01B |
| Current Liabilities | $1.40B | $1.02B | $1.02B | $1.02B | $1.02B | $910.65M | $910.65M | $910.65M |
| Accounts Payable | $308.92M | $278.16M | $278.16M | $278.16M | $278.16M | $237.73M | $237.73M | $237.73M |
| Long-Term Debt | $399.42M | $658.39M | $658.39M | $658.39M | $658.39M | $697.31M | $697.31M | $697.31M |
| Stockholders Equity | $5.97B | $4.13B | $4.86B | $4.86B | $4.86B | $3.36B | $4.13B | $4.13B |
Cash Flow Statement
| ๊ธฐ๊ฐ | 2027 Q1 | 2026 FY | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 FY | 2025 Q3 | 2025 Q2 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $457.32M | $1.40B | $1.21B | $634.16M | $325.54M | $693.30M | $961.15M | $559.12M |
| Investing Cash Flow | $-52.58M | $-269.78M | $-66.33M | $-34.55M | $2.15M | $-1.16B | $-223.28M | $-190.12M |
| Financing Cash Flow | $-230.27M | $-1.12B | $-442.37M | $-298.30M | $-150.76M | $422.87M | $-726.00M | $-390.09M |
| Stock Repurchases | $150.01M | $150.01M | $200.02M | $124.99M | $50.01M | $0 | $100.01M | $50.01M |
์ ์ฌ ๊ธฐ์
BAXTER INTERNATIONAL INC
BAX
BECTON DICKINSON & CO
BDX
BOSTON SCIENTIFIC CORP
BSX
DEXCOM INC
DXCM
3M CO
MMM
INSULET CORP
PODD
Solventum Corp
SOLV
STRYKER CORP
SYK
๋ ์์๋ณด๊ธฐ
How to Find Any SEC Filing in Two MinutesCash-Flow Quality: Profit Is an Opinion, Cash Is a FactValuation Basics: P/E, P/S and What They Actually Tell YouDividends: How Companies Pay Shareholders and How to Read ThemHow to Read a 10-K Annual Report (Without Falling Asleep)Understanding Earnings Per Share (EPS)How to Read a Cash Flow StatementHow to Read a Balance SheetHow to Read an Income Statement
๋ฐ์ดํฐ๋ ๋ฏธ๊ตญ SEC EDGAR ๊ณต๊ณต ๋ฐ์ดํฐ๋ฒ ์ด์ค์์ ์์ง๋์์ต๋๋ค. ์ด ์ฌ์ดํธ๋ ํฌ์ ์กฐ์ธ์ ์ ๊ณตํ์ง ์์ต๋๋ค.